{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:43:35Z","timestamp":1785285815444,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":405,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Knowledge of the effects of sex in cardio-oncology is limited, particularly in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML). This study aims to evaluate the influence of gender differences on the incidence of cardiovascular toxicity in patients with CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study population consisted of 148 patients (45% women, mean age: 58 \u00b1 14.2 years) diagnosed with CML treated with TKIs. The HFA-ICOS score estimated cardiovascular risk. The HFA-ICOS score revealed that 12% of men and 6% of women were categorized as very high risk while 45% of men and 50% of women fell into the high-risk group. Myocardial ischaemia, peripheral artery disease, venous thromboembolism, pulmonary hypertension and new-onset arterial hypertension during treatment with TKIs were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence of global events between men and women was comparable (35% vs 32%, P = 0.68). There were 33% who experienced a cardiovascular event during TKI therapy, with a significant sex difference in arterial thrombosis incidence (P = 0.02) and venous thrombosis incidence (P = 0.02). Patients treated with ponatinib had a 41% event rate, followed by nilotinib (32%) and imatinib (32%). The HFA-ICOS score demonstrated greater predictive efficacy for events in the female group [area under the curve (AUC) = 0.797] compared with the male group (AUC = 0.537). Very high [hazard ratio (HR) 3.07; confidence interval (CI) 1.11, 8.47 P = 0.03] and high (HR 3.29; CI 1.17, 9.26 P = 0.02) HFA-ICOS scores were associated with increased event risk, particularly in women. Diabetes was women's strongest predictor of events (HR 5.40; CI 1.37, 21.3 P = 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study showed a similar frequency of cardiovascular events between men and women. Accurate cardiovascular risk stratification with HFA-ICOS score in cancer patients is crucial. Diabetes and the HFA-ICOS score were significant predictors of events in the female groups. A sex approach in clinical practice could be pursued to improve the appropriateness of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15165","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T03:58:11Z","timestamp":1736395091000},"page":"1447-1454","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cardiovascular Toxicity Induced by TKIs in Patients with Chronic Myeloid Leukaemia: Are Women and Men Different?"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-4335","authenticated-orcid":false,"given":"Cristina","family":"Madaudo","sequence":"first","affiliation":[{"name":"Cardiology Unit, University Hospital \u2018Paolo Giaccone\u2019, Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo , Palermo ,","place":["Italy"]},{"name":"British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Di Lisi","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital \u2018Paolo Giaccone\u2019, Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cannat\u00e0","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Manfr\u00e8","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital \u2018Paolo Giaccone\u2019, Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Vullo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital \u2018Paolo Giaccone\u2019, Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Santoro","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Hospital \u2018Paolo Giaccone\u2019 , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Botta","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Hospital \u2018Paolo Giaccone\u2019 , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatrice","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Hospital \u2018Paolo Giaccone\u2019 , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Hospital \u2018Paolo Giaccone\u2019 , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Ruggero","family":"Galassi","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital \u2018Paolo Giaccone\u2019, Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital \u2018Paolo Giaccone\u2019, Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"2026021804064991600_ehf215165-bib-0001","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804064991600_ehf215165-bib-0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101604","article-title":"Gender and CVD- does it really matters?","volume":"48","author":"Suman","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2026021804064991600_ehf215165-bib-0003","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.974123","article-title":"Women at heart: introducing gender cardio-oncology","volume":"9","author":"Canale","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026021804064991600_ehf215165-bib-0004","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12889-021-10442-3","article-title":"Sex differences in factors associated with heart failure and diastolic left ventricular dysfunction: a cross-sectional population-based study","volume":"21","author":"Cesaroni","year":"2021","journal-title":"BMC Public Health"},{"key":"2026021804064991600_ehf215165-bib-0005","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s12094-023-03112-w","article-title":"Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualized approach","volume":"25","author":"Vera","year":"2023","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"2026021804064991600_ehf215165-bib-0006","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/CIRCULATIONAHA.122.058906","article-title":"Sex differences in cardio-oncology: considerations for the practicing clinician and researcher","volume":"145","author":"Okwuosa","year":"2022","journal-title":"Circulation"},{"key":"2026021804064991600_ehf215165-bib-0007","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/978-3-319-77932-4_27","article-title":"Sex-specific physiology and cardiovascular disease","volume":"1065","author":"Shufelt","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2026021804064991600_ehf215165-bib-0008","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3390\/jcm11175167","article-title":"Gender differences in diagnosis, prevention, and treatment of cardiotoxicity in cardio-oncology","volume":"11","author":"Simek","year":"2022","journal-title":"J Clin Med"},{"key":"2026021804064991600_ehf215165-bib-0009","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.2698","article-title":"Gender differences in cardio-oncology care of patients treated with immune checkpoint inhibitor therapy","volume":"44","author":"Mincu","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804064991600_ehf215165-bib-0010","doi-asserted-by":"publisher","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"2026021804064991600_ehf215165-bib-0011","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24183214","article-title":"Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy","volume":"24","author":"Wang","year":"2019","journal-title":"Mol Basel Switz"},{"key":"2026021804064991600_ehf215165-bib-0012","volume-title":"Chronic myelogenous leukemia","author":"Eden"},{"key":"2026021804064991600_ehf215165-bib-0013","volume-title":"Key Statistics for Chronic Myeloid Leukemia","author":"American Cancer Society"},{"key":"2026021804064991600_ehf215165-bib-0014","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2026021804064991600_ehf215165-bib-0015","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"2026021804064991600_ehf215165-bib-0016","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1053\/j.seminoncol.2019.01.007","article-title":"Cardiovascular events in cancer survivors","volume":"46","author":"Howard","year":"2019","journal-title":"Semin Oncol"},{"key":"2026021804064991600_ehf215165-bib-0017","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026021804064991600_ehf215165-bib-0018","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026021804064991600_ehf215165-bib-0019","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation"},{"key":"2026021804064991600_ehf215165-bib-0020","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","article-title":"Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer","volume":"332","author":"Lipshultz","year":"1995","journal-title":"N Engl J Med"},{"key":"2026021804064991600_ehf215165-bib-0021","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00277-019-03690-2","article-title":"Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors","volume":"98","author":"Ren","year":"2019","journal-title":"Ann Hematol"},{"key":"2026021804064991600_ehf215165-bib-0022","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood-2010-01-263764","article-title":"A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease","volume":"116","author":"Myrehaug","year":"2010","journal-title":"Blood"},{"key":"2026021804064991600_ehf215165-bib-0023","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804064991600_ehf215165-bib-0024","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Di Lisi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026021804064991600_ehf215165-bib-0025","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00021.2015","article-title":"Mechanistic pathways of sex differences in cardiovascular disease","volume":"97","author":"Regitz-Zagrosek","year":"2017","journal-title":"Physiol Rev"},{"key":"2026021804064991600_ehf215165-bib-0026","doi-asserted-by":"publisher","first-page":"37S","DOI":"10.1016\/j.jvs.2012.10.121","article-title":"Venous disease in women: epidemiology, manifestations, and treatment","volume":"57","author":"Lohr","year":"2013","journal-title":"J Vasc Surg"},{"key":"2026021804064991600_ehf215165-bib-0027","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.661464","article-title":"Arterial stiffness: effects of anticancer drugs used for breast cancer women","volume":"12","author":"Novo","year":"2021","journal-title":"Front Physiol"},{"key":"2026021804064991600_ehf215165-bib-0028","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"2026021804064991600_ehf215165-bib-0029","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"2026021804064991600_ehf215165-bib-0030","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.echo.2020.10.002","article-title":"Usefulness of stress echocardiography in the management of patients treated with anticancer drugs","volume":"34","author":"Novo","year":"2021","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr"},{"key":"2026021804064991600_ehf215165-bib-0031","doi-asserted-by":"publisher","first-page":"E159","DOI":"10.1002\/ajh.25102","article-title":"Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis","volume":"93","author":"Caocci","year":"2018","journal-title":"Am J Hematol"},{"key":"2026021804064991600_ehf215165-bib-0032","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/2\/1447\/66952891\/eschf_12_2_1447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/2\/1447\/66952891\/eschf_12_2_1447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:06:56Z","timestamp":1771405616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/2\/1447\/8488004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,9]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15165","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"2024-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}